

**PB 82 of 2025**

National Health (Minimum Stockholding) Amendment Determination (No. 6) 2025

I, Rebecca Richardson, as delegate of the Minister for Health and Ageing, make the following determination.

Dated 25 June 2025

Rebecca Richardson

Assistant Secretary
Pricing and PBS Policy Branch
Technology Assessment and Access Division
Department of Health, Disability and Ageing

Contents

1 Name 1

2 Commencement 1

3 Authority 1

4 Schedules 1

Schedule 1—Amendments commencing 1 July 2025 2

National Health (Minimum Stockholding) Determination 2023 2

Schedule 2—Amendments commencing 1 October 2025 6

National Health (Minimum Stockholding) Determination 2023 6

1 Name

 (1) This instrument is the *National Health (Minimum Stockholding) Amendment Determination (No. 6) 2025*.

 (2) This instrument may also be cited as PB 82 of 2025.

2 Commencement

1. Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

| Commencement information |
| --- |
| Column 1 | Column 2 | Column 3 |
| Provisions | Commencement | Date/Details |
| 1. Sections 1 to 4 and anything in this instrument not elsewhere covered by this table | 1 July 2025. | 1 July 2025 |
| 2. Schedule 1 | 1 July 2025. | 1 July 2025 |
| 3. Schedule 2 | 1 October 2025. | 1 October 2025 |

 (2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

3 Authority

 This instrument is made under subsection 99AEKC(2) of the *National Health Act 1953*.

4 Schedules

 Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.

Schedule 1—Amendments commencing 1 July 2025

National Health (Minimum Stockholding) Determination 2023

1 Schedule 1 (table)

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Amisulpride | Oral solution 100 mg per mL, 60 mL | Oral | Solian Solution | 4 months stock by reference to usual PBS demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Amisulpride | Tablet 400 mg | Oral | Amipride 400 | between 1 July 2025 to 31 August 2025—0 months stock by reference to usual demand |

2 Schedule 1 (table)

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Ceftriaxone | Powder for injection 2 g (as sodium) | Injection | Ceftriaxone Viatris | after 31 May 2024—6 months stock by reference to usual demand of both Ceftriaxone Viatris and Ceftriaxone Alphapharm added together |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Celecoxib | Capsule 100 mg | Oral | Blooms the Chemist Celecoxib | between 1 July 2025 to 31 August 2025—0 months stock by reference to usual demand |

3 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Doxorubicin | Solution for I.V. injection or intravesical administration containing doxorubicin hydrochloride 200 mg in 100 mL single dose vial | Injection/Intravesical | Adriamycin | between 1 June 2025 and 30 June 2025—0 months stock by reference to usual demand |

4 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Ezetimibe with simvastatin | Tablet 10 mg‑10 mg | Oral | Zeklen 10/10 mg | between 1 April 2025 and 30 June 2025—0 months stock by reference to usual demand |

5 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Ezetimibe with simvastatin | Tablet 10 mg‑20 mg | Oral | Zeklen 10/20 mg | between 1 April 2025 and 30 June 2025—0 months stock by reference to usual demand |

6 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Ezetimibe with simvastatin | Tablet 10 mg‑40 mg | Oral | Zeklen 10/40 mg | between 1 April 2025 and 30 June 2025—0 months stock by reference to usual demand |

7 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Ezetimibe with simvastatin | Tablet 10 mg‑80 mg | Oral | Zeklen 10/80 mg | between 1 April 2025 and 30 June 2025—0 months stock by reference to usual demand |

8 Schedule 1 (table)

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Fluconazole | Powder for oral suspension 50 mg in 5 mL, 35 mL | Oral | Diflucan | 4 months stock by reference to usual PBS demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Fluorouracil | Injection 5000 mg in 100 mL | Injection | Fluorouracil Ebewe | between 1 July 2025 to 31 July 2025—0 months stock by reference to usual demand |

9 Schedule 1 (table)

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Glyceryl trinitrate | Transdermal patch 54 mg | Transdermal | Minitran 15 | between 1 February 2025 and 31 December 2025—0 months stock by reference to usual demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Granisetron | Concentrated injection 3 mg (as hydrochloride) in 3 mL | Injection | Granisetron-AFT | between 1 July 2025 to 31 July 2025—0 months stock by reference to usual demand |

10 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Hypromellose with carbomer 980 | Ocular lubricating gel 3 mg-2 mg per g, 10 g | Application to the Eye | Genteal gel | between 1 October 2024 and 30 June 2025—0 months stock by reference to usual demand |
| Hypromellose with carbomer 980 | Ocular lubricating gel 3 mg-2 mg per g, 10 g | Application to the Eye | HPMC PAA | between 1 October 2024 and 30 June 2025—0 months stock by reference to usual demand |

11 Schedule 1 (table)

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Irbesartan with hydrochlorothiazide | Tablet 150 mg-12.5 mg | Oral | AVSARTAN HCT 150/12.5 | 4 months stock by reference to usual demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Irbesartan with hydrochlorothiazide | Tablet 150 mg-12.5 mg | Oral | Blooms the Chemist Irbesartan HCTZ 150/12.5 | between 1 July 2025 to 31 August 2025—0 months stock by reference to usual demand |
| Irbesartan with hydrochlorothiazide | Tablet 300 mg-12.5 mg | Oral | Blooms the Chemist Irbesartan HCTZ 300/12.5 | between 1 July 2025 to 31 August 2025—0 months stock by reference to usual demand |

12 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Sumatriptan | Tablet 50 mg (as succinate) | Oral | Imigran | between 1 April 2025 and 30 June 2025—0 months stock by reference to usual demand |
| Sumatriptan | Tablet 50 mg (as succinate) | Oral | Imigran Migraine | between 1 April 2025 and 30 June 2025—0 months stock by reference to usual demand |

13 Schedule 1 (table)

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Vancomycin | Powder for injection 500 mg (500,000 I.U.) (as hydrochloride) | Injection | Vancomycin Viatris | 4 months stock by reference to usual demand of both Vancomycin Viatris and Vancomycin Alphapharm added together |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Vinorelbine | Solution for I.V. infusion 50 mg (as tartrate) in 5 mL | Injection | Navelbine | between 1 July 2025 to 31 August 2025—0 months stock by reference to usual demand |

Schedule 2—Amendments commencing 1 October 2025

National Health (Minimum Stockholding) Determination 2023

1 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Acarbose | Tablet 50 mg | Oral | Acarbose Viatris | after 30 July 2024—4 months stock by reference to usual demand of both Acarbose Viatris and Acarbose Mylan added together |

2 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Azithromycin | Tablet 500 mg (as dihydrate) | Oral | Azithromycin Viatris | after 30 September 2024—4 months stock by reference to usual demand of both Azithromycin Viatris and Azithromycin Mylan added together |

3 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Cefazolin | Powder for injection 2 g (as sodium) | Injection | Cephazolin Viatris | after 30 July 2024—6 months stock by reference to usual demand of both Cephazolin Viatris and Cephazolin Alphapharm added together |

substitute:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Cefazolin | Powder for injection 2 g (as sodium) | Injection | Cephazolin Viatris | 6 months stock by reference to usual demand  |

4 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Ceftriaxone | Powder for injection 2 g (as sodium) | Injection | Ceftriaxone Viatris | after 31 May 2024—6 months stock by reference to usual demand of both Ceftriaxone Viatris and Ceftriaxone Alphapharm added together |

substitute:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Ceftriaxone | Powder for injection 2 g (as sodium) | Injection | Ceftriaxone Viatris | 6 months stock by reference to usual demand  |

5 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Entecavir | Tablet 1 mg (as monohydrate) | Oral | Entecavir Viatris | after 28 February 2025— 4 months stock by reference to usual demand of both Entecavir Viatris and Entecavir Mylan added together |

6 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Lercanidipine | Tablet containing lercanidipine hydrochloride 20 mg | Oral | ARX-LERCANIDIPINE | 6 months stock by reference to usual demand of both Lercanidipine APOTEX and ARX-LERCANIDIPINE added together |

substitute:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Lercanidipine | Tablet containing lercanidipine hydrochloride 20 mg | Oral | ARX-LERCANIDIPINE | 6 months stock by reference to usual demand  |

7 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Montelukast | Tablet, chewable, 5 mg (as sodium) | Oral | APX-Montelukast | 4 months stock by reference to usual demand of both Montelukast APOTEX and APX-Montelukast added together |

8 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Olanzapine | Tablet 10 mg | Oral | APO-OLANZAPINE | 4 months stock by reference to usual demand of both Olanzapine APOTEX and APO-OLANZAPINE added together |

9 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Tenofovir | Tablet containing tenofovir disoproxil maleate 300 mg | Oral | Tenofovir Disoproxil Viatris | after 31 January 2025— 4 months stock by reference to usual demand of both Tenofovir Disoproxil Viatris and Tenofovir Disoproxil Mylan added together |

10 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Tenofovir with emtricitabine | Tablet containing tenofovir disoproxil fumarate 300 mg with emtricitabine 200 mg | Oral | TENOFOVIR/EMTRICITABINE 300/200 ARX | 3 months stock by reference to usual demand of both Tenofovir/Emtricitabine 300/200 APOTEX and TENOFOVIR/EMTRICITABINE 300/200 ARX added together |

substitute:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Tenofovir with emtricitabine | Tablet containing tenofovir disoproxil fumarate 300 mg with emtricitabine 200 mg | Oral | TENOFOVIR/EMTRICITABINE 300/200 ARX | 3 months stock by reference to usual demand  |